Phase I/II triple therapy study of umbralisib and ublituximab ("U2") combined with checkpoint inhibition in patients with rel/ref CLL and Richter's transformation Meeting Abstract
| Authors: | Mato, A.; Svoboda, J.; Luning-Prak, E.; Schuster, S.; Tsao, P.; Dorsey, C.; Sarmasti, L.; Becker, P.; Brander, D.; Geyer, M.; Park, J.; Deonarine, I.; King, C.; Morrigan, B.; Elwell, J.; Kennard, K.; Roeker, L.; Zelenetz, A.; Purdom, M.; Paskalis, D.; Sportelli, P.; Miskin, H.; Weiss, M.; Shadman, M. |
| Abstract Title: | Phase I/II triple therapy study of umbralisib and ublituximab ("U2") combined with checkpoint inhibition in patients with rel/ref CLL and Richter's transformation |
| Meeting Title: | 18th International Workshop on Chronic Lymphocytic Leukemia |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 61 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Sept 20-23 |
| Meeting Location: | Edinburgh, United Kingdom |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2020-01-01 |
| Start Page: | 20 |
| End Page: | 21 |
| Language: | English |
| ACCESSION: | WOS:000534385400017 |
| PROVIDER: | wos |
| PUBMED: | 32436402 |
| DOI: | 10.1080/10428194.2020.1732667 |
| Notes: | Meeting Abstract: 1940 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
